Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions DOI Open Access
Martina Maria Capelletti,

Orsola Montini,

Emilio Ruini

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 26(1), P. 45 - 45

Published: Dec. 24, 2024

Genetic studies of haematological cancers have pointed out the heterogeneity leukaemia in its different subpopulations, with distinct mutations and characteristics, impacting treatment response. Next-generation sequencing (NGS) genome-wide analyses, as well single-cell technologies, offered unprecedented insights into clonal within same tumour. A key component this that remains unexplored is intracellular metabolome, a dynamic network determines cell functions, signalling, epigenome regulation, immunity inflammation. Understanding metabolic diversities among cancer cells their surrounding environments therefore essential unravelling complexities improving therapeutic strategies. Here, we describe currently available methodologies approaches to addressing progression. In second section, focus on leukaemic vulnerabilities acute myeloid (AML) lymphoblastic (ALL). Lastly, provide comprehensive overview most interesting clinical trials designed target these dependencies, highlighting potential advance strategies treatment. The integration multi-omics data for identification states tumour will enable “micro-to-macro” approach refinement practices delivery personalised therapies.

Language: Английский

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug DOI Creative Commons
Alice Njolke Mafe, Dietrich Büsselberg

Biomedicines, Journal Year: 2025, Volume and Issue: 13(2), P. 422 - 422

Published: Feb. 10, 2025

The intricate relationship between anticancer drugs and the gut microbiome influences cancer treatment outcomes. This review paper focuses on role of integrity in enhancing efficacy safety drug therapy, emphasizing pharmacokinetic interactions microbiota. It explores how disruptions to composition, or dysbiosis, can alter metabolism, immune responses, side effects. By examining mechanisms disruption caused by drugs, this highlights specific case studies like cyclophosphamide, 5-fluorouracil, irinotecan, their impact microbial diversity clinical also discusses microbiome-targeted strategies, including prebiotics, probiotics, postbiotics, fecal microbiota transplantation (FMT), as promising interventions enhance treatment. Furthermore, potential profiling personalizing therapy integrating these into practice is explored. Finally, proposes future research directions, developing novel biomarkers a deeper comprehension drug-microbiome interactions, respond current gaps knowledge improve patient outcomes care.

Language: Английский

Citations

1
Therapeutic Potential of Fungal Polysaccharides in Gut Microbiota Regulation: Implications for Diabetes, Neurodegeneration, and Oncology DOI Creative Commons
Alexandru Stefan Barcan,

Rares Andrei Barcan,

Emanuel Vamanu

et al.

Journal of Fungi, Journal Year: 2024, Volume and Issue: 10(6), P. 394 - 394

Published: May 31, 2024

This review evaluates the therapeutic effects of polysaccharides derived from mushroom species that have medicinal and edible properties. The fungal were recently studied, focusing on their modulation gut microbiota impact various diseases. study covers both clinical preclinical studies, detailing results highlighting significant influence these modulation. It discusses potential health benefits incorporating into diet for managing chronic diseases such as diabetes, neurodegenerative disorders, cancer. Furthermore, emphasizes interaction between microbiota, underscoring role in modulating microbial community. presents a systematic analysis findings, demonstrating substantial composition function, which may contribute to conditions. We conclude by play crucial mediating effects, offering promising avenue further research applications disease prevention treatment.

Language: Английский

Citations

6
The role of microbiome in CAR-T cell therapy DOI
Reham Abdel‐Wahab, Travis Kerr, Daniel J. McGrail

et al.

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy DOI Open Access

P. Kim,

Sook-Haeng Joe, Heeyoung Kim

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 856 - 856

Published: Jan. 20, 2025

Recent studies have highlighted that the microbiome is essential factor can modulate clinical activity of immunotherapy. However, role varies significantly across different immunotherapies, suggesting it critical to understand precise function in each type While many previous primarily focus on summarizing immune checkpoint inhibitors, we seek explore a novel aspect other immunotherapies such as mesenchymal stem cell therapy, chimeric antigen receptor T and antibodies-based therapy (e.g., adalimumab, infliximab, bevacizumab, denosumab, etc.) which are rarely summarized reviews. Moreover, highlight innovative strategies for utilizing microbial metabolites enhance response Collectively, believe our manuscript will provide insights approaches researchers, could drive development next generation personalized therapeutic interventions using microbiomes.

Language: Английский

Citations

0
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges DOI
Hinrich Abken

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Language: Английский

Citations

0
The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy DOI Creative Commons
Lingling Yin, Bin Lv,

Jiao Ge

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: April 17, 2025

In recent years, chimeric antigen receptor (CAR)-T cell therapy has achieved tremendous efficacy in relapsed/refractory multiple myeloma (R/R MM). However, the impact of antibiotic (ATB) use on R/R MM patients treated with CAR-T is still not known. The aim our study was to analyse influence ATB clinical outcomes cells. this retrospective study, 199 who received cells between January 2018 and December 2023 were evaluated from two hospitals China. They stratified into ATB-group No according whether administered 4 weeks before therapy. We mainly analyzed efficacy, survival cytotoxicity groups patients. group (90 patients), overall response rate (ORR) 70% comparable (109 patients: ORR, 81.7%; P = 0.054). complete (CRR) 40%, which significantly lower compared (CRR, 57.8%; 0.012). median progression-free (PFS) 6.7 months while (OS) 21.9 for group. PFS OS 13.9 36.1 months. There significant differences (P 0.007) 0.004) groups. Nonetheless, multivariate analysis found did reduce CRR (odds ratio [OR], 0.947; 95% confidence interval [CI], 0.251 3.565, 0.936). Besides, administration affect (hazard [HR], 0.634; CI, 0.28 1.436, 0.275) (HR, 2.259; 0.755 6.762, 0.145) Additionally, both had similar incidences cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS). Our results point a detrimental effect treatment associated incidence CRS or ICANS.

Language: Английский

Citations

0
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review DOI Open Access
Romana Masnikosa, Zorica Cvetković, David Pirić

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11384 - 11384

Published: Oct. 23, 2024

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline tumor biology behind actual potential drug targets address challenges drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody-drug conjugates, chimeric antigen receptors, bispecific antibodies T-cell engagers, immune checkpoint inhibitors. Candidate drugs explored in ongoing trials diverse toxicity issues refractoriness drugs. According literature DLBCL, promise for new therapeutic lies epigenetic alterations, receptor NF-κB pathways. present putative hiding lipid pathways, ferroptosis, gut microbiome that could be used addition immuno-chemotherapy improve general health status patients, thus increasing chance being cured. It may time devote more effort exploring metabolism discover novel druggable targets. We also performed bibliometric knowledge-map analysis published from 2014-2023.

Language: Английский

Citations

1
Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy DOI Creative Commons

Kartik Bhatnagar,

Kanupriya Jha,

Nishu Dalal

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 29, 2024

The human microbiome is the complex ecosystem consisting of trillions microorganisms that play a key role in developing immune system and nutrient metabolism. Alterations gut have been linked to cancer initiation, progression, metastasis, response treatment. Accumulating evidence suggests levels vitamins minerals influence environment may implications for risk progression. Bifidobacterium has reported reduce colorectal by binding free iron. Additionally, zinc ions shown activate cells enhance effectiveness immunotherapy. Higher selenium associated with reduced several cancers, including cancer. In contrast, enhanced copper uptake implicated promoting colon interaction between bacteria, as well dysbiosis impact studied animal models. interplay prebiotics, probiotics, synbiotics, postbiotics bacteria offers diverse physiological benefits. We also explored particular probiotic formulations like VSL#3, Prohep,

Language: Английский

Citations

1
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions DOI Open Access
Martina Maria Capelletti,

Orsola Montini,

Emilio Ruini

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 26(1), P. 45 - 45

Published: Dec. 24, 2024

Genetic studies of haematological cancers have pointed out the heterogeneity leukaemia in its different subpopulations, with distinct mutations and characteristics, impacting treatment response. Next-generation sequencing (NGS) genome-wide analyses, as well single-cell technologies, offered unprecedented insights into clonal within same tumour. A key component this that remains unexplored is intracellular metabolome, a dynamic network determines cell functions, signalling, epigenome regulation, immunity inflammation. Understanding metabolic diversities among cancer cells their surrounding environments therefore essential unravelling complexities improving therapeutic strategies. Here, we describe currently available methodologies approaches to addressing progression. In second section, focus on leukaemic vulnerabilities acute myeloid (AML) lymphoblastic (ALL). Lastly, provide comprehensive overview most interesting clinical trials designed target these dependencies, highlighting potential advance strategies treatment. The integration multi-omics data for identification states tumour will enable “micro-to-macro” approach refinement practices delivery personalised therapies.

Language: Английский

Citations

0